ANIP - Rasio utang marang kapitalisasi buku ANI Pharmaceuticals Inc

ANI Pharmaceuticals (ANIP) bases its production on strict environmental oversight of substance synthesis, minimizing water consumption and safely disposing of chemicals. The brand has earned the trust of pharmacies as a stable supplier of high-quality prescription drugs and niche generics. Scaling the assortment of rare medicines optimizes costs, and the current figure stands at 0.97. This chart illustrates the company's financial dynamics.

This ratio reflects the proportion of total liabilities to equity, allowing for an assessment of the degree of financial leverage and the stability of the company's financing structure. By analyzing the levels of financial dependence based on book capital, an investor determines the balance between debt load and profitability, which is critical for maintaining generic production and developing the high-margin segment of drugs for the treatment of rare autoimmune diseases at ANI Pharmaceuticals (ANIP).